Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023.
Euro Surveill
; 29(17)2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38666403
ABSTRACT
The BPaLM regimen (bedaquiline, pretomanid, linezolid and moxifloxacin) recently recommended by the World Health Organization offers short, safe, and effective treatment for multidrug-resistant/rifampicin-resistant tuberculosis (TB). In a survey with national TB focal points in 18 central and western European countries to explore barriers for the implementation of BPaLM, only three reported full availability of pretomanid, a necessary component of this regimen. Implementation barriers included financing and procurement. Solutions on national and supranational level are needed to guarantee universal access.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Rifampina
/
Organização Mundial da Saúde
/
Tuberculose Resistente a Múltiplos Medicamentos
/
Linezolida
/
Antituberculosos
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
En
Revista:
Euro Surveill
Ano de publicação:
2024
Tipo de documento:
Article